Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?

被引：0
作者：
Patel, Shruti R. [1 ,2 ]
Neal, Joel W.
机构：
[1] Stanford Univ, Stanford Canc Inst, Dept Med, Div Med Oncol, Palo Alto, CA USA
[2] Stanford Univ, Stanford Canc Inst, Dept Med Oncol, Palo Alto, CA 94305 USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 07期
关键词：
Osimertinib; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); adjuvant; ADAURA;
D O I：
10.21037/tlcr-23-273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1631 / 1635
页数：5
相关论文
共 50 条
  • [41] Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 44 - 54
  • [42] Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib
    Benyounes, A.
    Cohen, A.
    Rossi, S. Diamond
    Cannon, T.
    Yacur, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S657 - S657
  • [43] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [44] Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
    Hori, Tomoki
    Yamamoto, Kazuhiro
    Ito, Takefumi
    Ikushima, Shigeki
    Omura, Tomohiro
    Yano, Ikuko
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 281 - 288
  • [45] Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer
    Chevallier, Mathieu
    Tsantoulis, Petros
    Addeo, Alfredo
    Friedlaender, Alex
    CANCER GENOMICS & PROTEOMICS, 2020, 17 (05) : 597 - 603
  • [46] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [47] Long-term survival of a non-small cell lung cancer patient with EGFR-mutated brain metastases: a case report
    Wan, Yuming
    Xu, Feng
    Wang, Jin
    TRANSLATIONAL CANCER RESEARCH, 2022, : 4448 - 4454
  • [48] Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
    Xiao-Ming Jiang
    Yu-Lian Xu
    Mu-Yang Huang
    Le-Le Zhang
    Min-Xia Su
    Xiuping Chen
    Jin-Jian Lu
    Acta Pharmacologica Sinica, 2017, 38 : 1512 - 1520
  • [49] Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer
    Wakelee, Heather
    Chhatwani, Laveena
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 198 - 203
  • [50] The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
    Melosky, Barbara
    Cheema, Parneet
    Juergens, Rosalyn A.
    Leighl, Natasha B.
    Liu, Geoffrey
    Wheatley-Price, Paul
    Sacher, Adrian
    Snow, Stephanie
    Tsao, Ming-Sound
    McLeod, Deanna
    Chu, Quincy
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
12345